Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

Andrew M. Evens, DO, MSc, Mitchell R Smith, MD, PhD, Izidore S Lossos, MD, Borko Jovanovic, PhD, Adam Cohen, MD, Jane N. Winter, MD, Steven T. Rosen, MD, FRCPA, Leo I. Gordon, MD

Blood (2012) 120 (21): 1642.

https://doi.org/10.1182/blood.V120.21.1642.1642

Published: 2012

Journal Articles

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Jatin J. Shah, M.D., Jeffrey A. Zonder, MD, Adam Cohen, MD, William Bensinger, MD, Jonathan L. Kaufman, MD, Robert Z. Orlowski, M.D., Ph.D., R. Donald Harvey, PharmD, Muneer H. Abidi, MD, Sheeba K. Thomas, MD, Duncan Walker, PhD, Brandi Hilder, Ann Marie Ptaszynski, MD, Sagar Lonial, MD

Blood (2012) 120 (21): 449.

https://doi.org/10.1182/blood.V120.21.449.449

Published: 2012

Journal Articles

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Heather Landau, MD, Hani Hassoun, MD, Michael A. Rosenzweig, MD, Christina Bello, Elizabeth Hoover, Elyn Riedel, Alex Lesokhin, MD, Nikoletta Lendvai, MD, PhD, Adam Cohen, MD, Stephen Nimer, Raymond L. Comenzo, MD

Blood (2010) 116 (21): 2391.

https://doi.org/10.1182/blood.V116.21.2391.2391

Published: 2010

Journal Articles

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

James E. Hoffman, MD, Hani Hassoun, MD, Heather Landau, MD, Elizabeth Hoover, Adam Cohen, MD, Stephen Nimer, MD, Raymond Comenzo, MD

Blood (2008) 112 (11): 3329.

https://doi.org/10.1182/blood.V112.11.3329.3329

Published: 2008

Journal Articles

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Heather Landau, MD, Hani Hassoun, MD, Adam Cohen, MD, Elizabeth Hoover, Tarun Kewalramani, MD, Adam Boruchov, MD, Virginia Klimek, MD, Lillian Reich, MD, Elyn Riedel, Neeta Pandit-Taskar, MD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2008) 112 (11): 3712.

https://doi.org/10.1182/blood.V112.11.3712.3712

Published: 2008

Journal Articles

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

James Lee, BA, Yan Nikhamin, MS, Gavin Imperato, MS, Adam Cohen, MD, Michel Sadelain, MD/PhD, Renier Brentjens, MD/PhD

Blood (2007) 110 (11): 2754.

https://doi.org/10.1182/blood.V110.11.2754.2754

Published: 2007

Journal Articles

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Hani Hassoun, MD, Brian T. Rafferty, MS, Carlos Flombaum, MD, Vivette D. D’Agati, MD, Virginia M. Klimek, MD, Adam Cohen, MD, Adam Boruchov, MD, Tarun Kewalramani, MD, Lilian Reich, MD, Heather Landau, MD, Stephen D. Nimer, MD, Raymond Comenzo, MD

Blood (2007) 110 (11): 5113.

https://doi.org/10.1182/blood.V110.11.5113.5113

Published: 2007

Journal Articles

Predictors of Survival in De Novo Cardiac Amyloidosis.

Raymond L. Comenzo, MD, Mathew Maurer, MD, Adam Cohen, MD, Hani Hassoun, MD, Ping Zhou, PhD, Ping Lu, PhD, Martin Fleisher, PhD, Daniel Lebovic, MD, Julie Feldstein, MD, Richard Steingart, MD, Stephen D. Nimer, MD

Blood (2007) 110 (11): 2870.

https://doi.org/10.1182/blood.V110.11.2870.2870

Published: 2007

Journal Articles

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

Hani Hassoun, MD, Lilian Reich, MD, Virginia M. Klimek, MD, Madhav Dhodapkar, MD, Adam Cohen, MD, Tarun Kewalramani, MD, Elyn R. Riedel, MA, Cyrus V. Hedvat, MD, Julie Teruya-Feldstein, MD, Daniel A. Filippa, MD, Martin Fleisher, PhD, Stephen D. Nimer, MD, Raymond L. Comenzo, MD

Blood (2005) 106 (11): 3481.

https://doi.org/10.1182/blood.V106.11.3481.3481

Published: 2005

Journal Articles

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.

Adi Diab, MD, Vanessa M. Hubbard, Adam Cohen, MD, Deonka Huggins, Adam Kochman, Jose A. Guevarra, MD, Manuel Engelhorn, PhD, Jedd D. Wolchok, MD, PhD, Marcel van den Brink, MD, PhD, Alan N. Houghton, MD, Miguel-Angel Perales, MD

Blood (2004) 104 (11): 3057.

https://doi.org/10.1182/blood.V104.11.3057.3057

Published: 2004

Journal Articles

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Adi Diab, MD, Miguel-Angel Perales, MD, Adam Cohen, MD, Vanessa M. Hubbard, Jeff Eng, Deonka Huggins, Manuel Engelhorn, PhD, Jose A. Guevarra, MD, Onder Alpdogan, MD, Jedd D. Wolchok, MD, PhD, Adam Kochman, Alan N. Houghton, MD, Marcel van den Brink, MD, PhD

Blood (2004) 104 (11): 304.

https://doi.org/10.1182/blood.V104.11.304.304

Published: 2004

NARROW

A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)

The Novel KSP Inhibitor ARRY-520 Is Active Both with and without Low-Dose Dexamethasone in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide: Results From a Phase 2 Study

Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy

Early Adjuvant Treatment after Risk-Adapted Autologous Stem Cell Transplant for Systemic Light-Chain Amyloidosis: Increased Hospitalizations and Impaired Immune Recovery but Improved Responses and Overall Survival.

Sequential Administration of Bortezomib, Liposomal Doxorubicin and Dexamethasone (BDD) Followed by Thalidomide and Dexamethasone (TD) Results in Rapid Control of Untreated High-Risk Multiple Myeloma (MM) and Improves Depth of Response

Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy.

High Dose Chemotherapy and Autologous Stem Cell Transplantation with Melphalan in Patients with Monoclonal Immunoglobulin Deposition Disease Associated with Multiple Myeloma.

Predictors of Survival in De Novo Cardiac Amyloidosis.

The Serum Free Light Chain Ratio after One or Two Cycles of Treatment Is Highly Predictive of the Magnitude of Final Response in Patients Undergoing Initial Treatment for Multiple Myeloma.

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution.

DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only